DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Coutre SE, Leonard J, Furman R et al.
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study.
Blood ASH Annual Meeting Abstract 2012;
210
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.